Chicamanguya virus (CHIKV) is an insect-borne infectious agent that can cause severe disease in humans and against which there is presently no vaccine. This alphavirus has infected millions of people in Africa, Europe, and Asia since it reemerged in Kenya in 2004. The severity of the disease and the epidemic spread of the virus present a serious public health threat in the absence of vaccines or antiviral therapies. Although seldom fatal, infection with the virus causes highly painful arthritis-like symptoms that can linger for months or even years. CHIKV is capable of adapting to spread through a mosquito species common in much of North America. The virus has been the focus of intense scientific interest ever since a 2006 outbreak on the island of La Reunion in the Indian Ocean infected approximately 266,000 people, killing 260 of them. The name “chicamanguya” comes from an East African tribal word describing the contorted postures of the virus’s pain-wracked victims. Now, scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators have reported development of a virus-like particle (VLP) vaccine that protects rhesus macaques against infection by CHIKV. "This vaccine did an excellent job of protecting the macaques from chikungunya," said Dr. Stephen Higgs, one of the paper's authors.
Login Or Register To Read Full Story